VCEL Vericel Corporation

Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 3rd Quarter Fiscal Year 2007 Investor Conference Call When: Tuesday, May 8, 2007 @ 9:00 am (EDT) Where: http://www.vcall.com/IC/CEPage.asp?ID=115723 How: � For live Internet access, simply log on to the web at the address above. � For phone access, interested parties should call toll-free (877) 407-9205 before the start of the call to register and identify themselves as registrants of the �Aastrom Conference Call�. Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8054. � To download the podcast, simply log on to the web at the address above. Contact: Investor Relations Department, (734) 930-5777 or mail@aastrom.com If you are unable to participate during the live call, the webcast will be available for replay at http://www.investorcalendar.com/ for 60 days. Through May 18, 2007, the audio replay of the call�will be available by dialing toll-free�(877) 660-6853, or from outside the U.S. (201) 612-7415. When prompted on the phone, the Account # is: 286, and the Conference ID# is: 237442. Aastrom is a regenerative medicine company developing autologous cell products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell (TRC) Technology. Aastrom's TRC-based products are a unique cell mixture of stem and progenitor cells, produced from a small amount of bone marrow taken from the patient. TRC-based products have been used in over 250 patients, and are currently in clinical trials for bone regeneration (osteonecrosis of the femoral head, long bone fractures and spine fusion) and vascular regeneration (critical limb ischemia) applications. Aastrom has reported positive interim clinical trial results suggesting both the clinical safety and the ability of TRC products to promote healing in bone regeneration applications. The Company is also developing programs for TRC-based therapies to address cardiac and neural regeneration indications. TRCs have received Orphan Drug Designation from the FDA for use in the treatment of osteonecrosis of the femoral head and the treatment of dilated cardiomyopathy, a severe chronic disease of the heart. For more information, visit Aastrom�s website at www.aastrom.com. (astmc)